Haloperidol decanoate

Haloperidol decanoate is a depot preparation of haloperidol, a commonly used butyrophenone derivative with antipsychotic activity. Haloperidol decanoate can increase the striatal D2 receptor in rat. Haloperidol decanoate can improve conditions of psychoses (mainly schizophrenia) . Haloperidol decanoate can lead to increased accumulation of the dopamine metabolites homo-vanillic acid. Haloperidol decanoate can reduce intestinal transport, increase gastric emptying and reduce acid output in rat model[1][4].

Product Specifications

CAS Number

[74050-97-8]

UNSPSC

12352005

Hazard Statement

H302, H413

Target

COX; Dopamine Receptor; NO Synthase

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/haloperidol-decanoate.html

Purity

99.67

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CCCCCCCCCC(OC1(C2=CC=C(Cl)C=C2)CCN(CCCC(C3=CC=C(F)C=C3)=O)CC1)=O

Molecular Formula

C31H41ClFNO3

Molecular Weight

530.11

Precautions

H302, H413

References & Citations

[1]R Beresford, et al. Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis. Drugs. 1987 Jan;33 (1) :31-49.|[2]Schmitz, I., et al., (2025) . A single dose of haloperidol decanoate induces short-term hippocampal neuroinflammation: focus on the glial response. Pharmacological reports : PR, 77 (3), 800–808. |[3]Oh-e, Y., et al., (1991) . Pharmacokinetics of haloperidol decanoate in rats. Journal of pharmacobio-dynamics, 14 (11), 615–622.|[4]Akiyama, K., et al., (1987) . Effect of chronic administration of haloperidol (intermittently) and haloperidol-decanoate (continuously) on D2 dopamine and muscarinic cholinergic receptors and on carbachol-stimulated phosphoinositide hydrolysis in the rat striatum. The Japanese journal of psychiatry and neurology, 41 (2), 311–320.